.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Queensland Health
US Department of Justice
Fuji
Mallinckrodt
Johnson and Johnson
Harvard Business School
Deloitte
QuintilesIMS
US Army

Generated: September 21, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 6,685,967 protect, and when does it expire?


Patent ► Subscribe protects EXUBERA and is included in one NDA.

This patent has two hundred and twenty-five patent family members in forty-four countries.

Summary for Patent: ► Subscribe

Title: Methods and compositions for pulmonary delivery of insulin
Abstract:Systemic delivery of insulin to a mammalian host is accomplished by inhalation of a dry powder of insulin. It has been found that dry insulin powders are rapidly absorbed through the alveolar regions of the lungs.
Inventor(s): Patton; John S. (San Carlos, CA), Foster; Linda (Sunnyvale, CA), Platz; Robert M. (Half Moon Bay, CA)
Assignee: Nektar Therapeutics (San Carlos, CA)
Application Number:08/668,036
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Process; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pfizer
EXUBERA
insulin recombinant human
POWDER;INHALATION021868-001Jan 27, 2006DISCNNoNo► Subscribe► SubscribeY
Pfizer
EXUBERA
insulin recombinant human
POWDER;INHALATION021868-002Jan 27, 2006DISCNNoNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,019,968 Dispersible antibody compositions and methods for their preparation and use► Subscribe
6,231,851 Methods and compositions for the dry powder formulation of interferons► Subscribe
6,051,256 Dispersible macromolecule compositions and methods for their preparation and use► Subscribe
7,138,141Dispersible macromolecule compositions and methods for their preparation and use► Subscribe
6,592,904 Dispersible macromolecule compositions and methods for their preparation and use► Subscribe
6,138,668 Method and device for delivering aerosolized medicaments► Subscribe
6,673,335 Compositions and methods for the pulmonary delivery of aerosolized medicaments► Subscribe
5,458,135 Method and device for delivering aerosolized medicaments► Subscribe
5,780,014 Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin► Subscribe
6,423,344 Dispersible macromolecule compositions and methods for their preparation and use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia740760► Subscribe
Australia1744995► Subscribe
Australia2369599► Subscribe
Australia2514295► Subscribe
Australia5083498► Subscribe
Australia5349694► Subscribe
Australia5482596► Subscribe
Australia5743996► Subscribe
Bulgaria102875► Subscribe
Bulgaria64113► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
US Army
Queensland Health
UBS
Cerilliant
Chubb
Mallinckrodt
Express Scripts
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot